Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS   US4643301090

Delayed Quote. Delayed Nasdaq - 04/24 04:00:00 pm
35.2 USD   --.--%
3d ago ISIS PHARMACEUTICALS : to Host Investor Event to Discuss ISIS-SMN Rx Data P..
4d ago ISIS PHARMACEUTICALS : Assigned Patent
04/14 ISIS PHARMACEUTICALS : Assigned Patent
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/17/2014 04/21/2014 04/22/2014 04/23/2014 04/24/2014 Date
34.01(c) 35.06(c) 37(c) 35.2(c) 35.2(c) Last
1 000 099 1 203 067 2 158 499 1 599 270 1 574 785 Volume
-1.62% +3.09% +5.53% -4.86% 0.00% Change
More quotes
Company
Isis Pharmaceuticals, Inc. engages in the development and commercialization of drugs to treat various health conditions, including inflammatory, viral, metabolic and cardiovascular and dermatological diseases and cancer. The company operates in two segments: Drug Discovery & Development and Regulus. 
Sector
Biotechnology
Calendar
04/29 | 06:00pmPresentation
Surperformance© rating of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More about the company
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 156 M
EBIT 2014 -76,9 M
Net income 2014 -94,4 M
Debt 2014 186 M
Yield 2014 -
Sales 2015 164 M
EBIT 2015 -73,3 M
Net income 2015 -92,8 M
Debt 2015 134 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 29,0x
EV / Sales 2015 27,2x
Capitalization 4 339 M
More Financials
Latest news on ISIS PHARMACEUTICALS, INC.
3d ago ISIS PHARMACEUTICALS : to Host Investor Event to Discuss ISIS-SMN Rx Data Presen..
4d ago ISIS PHARMACEUTICALS : Assigned Patent
04/14 ISIS PHARMACEUTICALS : Assigned Patent
04/01 ISIS PHARMACEUTICALS : to Present at the 13th Annual Needham Healthcare Conferen..
03/31 ISIS PHARMACEUTICALS : Reports Final Phase 2 Data On -APOCIII Rx In Patients Wit..
03/28 ISIS PHARMACEUTICALS : Biotech Stocks Analysis -- Research on Array BioPharma, A..
03/25 ISIS PHARMACEUTICALS : Assigned Patent
03/24 ISIS PHARMACEUTICALS : Announces Antisense Targeting Of HBV Produces Dose-Depend..
03/20 ISIS PHARMACEUTICALS : Assigned Patent
03/19 ISIS PHARMACEUTICALS : Patent Issued for Modulation of Prion Expression
03/19 ISIS PHARMACEUTICALS : Initiates Phase 1 Study of ISIS-ANGPTL3 Rx to Treat Hyper..
03/12 ISIS PHARMACEUTICALS : IWM, SSG: Big ETF Inflows
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
ISIS Pharmaceuticals, Inc. : Income Statement Evolution
More Financials
EPS Revisions
ISIS Pharmaceuticals, Inc. : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF